Better understanding of the molecular cause of these rare genetic conditions has led to successful treatment with targeted drug therapy such as MEK-inhibitors (e.g., Noonan syndrome, Neurofibromatosis type 1). This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.